Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual ...
Panelists discuss how the 5-year CROWN trial data for lorlatinib have shaped the treatment paradigm for ALK+ metastatic non-small cell lung cancer (NSCLC), particularly regarding long-term survival, ...
Outcomes of patients with concurrent chronic lymphocytic leukemia and non-small cell lung carcinoma. Circulating tumor DNA as a prognostic biomarker for long-term survival in de-novo oligometastatic ...
About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of their diagnosis. Metastatic NSCLC refers to ...
The American Cancer Society’s Cancer Statistics, 2026 report highlights a historic milestone: the 5-year relative survival rate for all cancers combined has reached 70%, up from 49% in the mid-1970s.
Please provide your email address to receive an email when new articles are posted on . Patients with rheumatoid arthritis who receive immune checkpoint inhibition for metastatic lung cancer have ...
A new study by researchers at Wake Forest University School of Medicine has identified a promising strategy to treat brain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results